Zobrazeno 1 - 10
of 40
pro vyhledávání: '"John S Bridgeman"'
Autor:
Mark Dudley, Gray Kueberuwa, John S Bridgeman, Martina Sykorova, Leyuan Bao, Robert E Hawkins, Katrina Sherbina Baklan, Owen Moon, Jinzhou Yuan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/094bf09ba2824d2f89844cf2d61005e0
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7e2a3d2133bc42ef929ff49564420d77
Autor:
Natalia Kirillova, Robert Hawkins, Gray Kueberuwa, Paul C Lorigan, Yizhou Jiang, Fiona C Thistlethwaite, Manon Pillai, Martine Thomas, John S Bridgeman, Ryan D Guest, Zachary J Roberts
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/484b249da0c542a8858fb606066fec68
Autor:
Frances E Pearson, Kirsteen M Tullett, Ingrid M Leal‐Rojas, Oscar L Haigh, Kelly‐Anne Masterman, Carina Walpole, John S Bridgeman, James E McLaren, Kristin Ladell, Kelly Miners, Sian Llewellyn‐Lacey, David A Price, Antje Tunger, Marc Schmitz, John J Miles, Mireille H Lahoud, Kristen J Radford
Publikováno v:
Clinical & Translational Immunology, Vol 9, Iss 6, Pp n/a-n/a (2020)
Abstract Objectives Vaccines that prime Wilms' tumor 1 (WT1)‐specific CD8+ T cells are attractive cancer immunotherapies. However, immunogenicity and clinical response rates may be enhanced by delivering WT1 to CD141+ dendritic cells (DCs). The C
Externí odkaz:
https://doaj.org/article/d7716a6649ca41f9a6290ec9da9eae79
Autor:
John S. Bridgeman, Matthew J. Spindler, Michael A. Asensio, Adam S. Adler, Robert E. Hawkins, Everett Meyer, James M. Heather, Ayla Nelson, Mark Cobbold, Ellen K. Wagner, Natasha Oppermans, Robert C. Edgar, David S. Johnson, Yoong Wearn Lim
Publikováno v:
Spindler, M J, Nelson, A L, Wagner, E K, Oppermans, N, Bridgeman, J S, Heather, J M, Adler, A S, Asensio, M A, Edgar, R C, Lim, Y W, Meyer, E H, Hawkins, R E, Cobbold, M & Johnson, D S 2020, ' Massively parallel interrogation and mining of natively paired human TCRαβ repertoires ', Nature biotechnology, vol. 38, no. 5, pp. 609-619 . https://doi.org/10.1038/s41587-020-0438-y
Nature biotechnology
Nature biotechnology
T cells engineered to express antigen-specific T cell receptors (TCRs) are potent therapies for viral infections and cancer. However, efficient identification of clinical candidate TCRs is complicated by the size and complexity of T cell repertoires
Autor:
Milena Kalaitsidou, Rubén Alvarez-Rodríguez, Leyuan Bao, Michelle Le Brocq, John S. Bridgeman, Gray Kueberuwa, Robert E. Hawkins, Martina Sykorova, Cynthia Chauvin-Fleurence
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundCostimulatory signals are a critical component to mount an effective anti-tumor response. Prolonged TCR stimulation in the absence of costimulatory signals can lead to T cell anergy and dysfunction. The tumor microenvironment evades immune
Autor:
Yong Ouyang, Clare Yarka, Michelle Mojadidi, Rubén Alvarez-Rodríguez, Bob Hawkins, John S. Bridgeman, Milena Kalaitsidou, Eric H. Gschweng, Gray Kueberuwa, Sujita Sukumaran
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundMajor limiting factors for cell therapy in solid tumors include clonal heterogeneity and the related lack of universally expressed tumor-specific antigens. As the only truly polyclonal cell product in advanced development, tumor infiltratin
Autor:
Martine Thomas, Gray Kueberuwa, John S. Bridgeman, Natalia Kirillova, Zachary J. Roberts, Ryan D. Guest, Yizhou Jiang, Paul Lorigan, Manon Pillai, Robert E. Hawkins, Fiona C Thistlethwaite
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundTumor infiltrating lymphocyte (TIL) products made from tumor digests showed a high overall response rate (ORR; 67%) and complete response (CR) rate (19%) and a safety profile consistent with lymphodepletion and high-dose interleukin (IL)-2
Autor:
Andrew K. Sewell, Anzelika Rubina, Sian Llewellyn-Lacey, John S. Bridgeman, Hugo A. van den Berg, Kelly L. Miners, Ore Francis, Linda Wooldridge, James E. McLaren, Lea Knezevic, Mathew Clement, David K. Cole, Kristin Ladell, David A. Price, Tamsin Dockree
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance Sufficient immune coverage of the peptide universe within a finite host requires highly degenerate T cell receptors (TCRs). However, this inherent need for antigen cross-recognition is associated with a high risk of autoimmunity, which c
Autor:
Owen R. Moon, Yun Qu, Michael G. King, Michelle Mojadidi, Cynthia Chauvin-Fleurence, Clare Yarka, Alicia Evans, Xingliang Zhou, Tania (Theoni) Katopodi, Akshata Udyavar, John S. Bridgeman, Gray Kueberuwa, Rubén Alvarez-Rodríguez
Publikováno v:
Journal of Clinical Oncology. 40:2535-2535
2535 Background: ITIL-306 is an autologous tumor-infiltrating lymphocyte (TIL) therapy that integrates T-cell receptor (TCR)-specific antigen recognition (Signal 1) with robust costimulation via the novel CoStAR transgene upon engagement with FOLR1 (